162 related articles for article (PubMed ID: 25278452)
1. Promising cell-based immunotherapy using gamma delta T cells: together is better.
Déchanet-Merville J
Clin Cancer Res; 2014 Nov; 20(22):5573-5. PubMed ID: 25278452
[TBL] [Abstract][Full Text] [Related]
2. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
[TBL] [Abstract][Full Text] [Related]
3. Molecular Determinants of Target Cell Recognition by Human γδ T Cells.
Simões AE; Di Lorenzo B; Silva-Santos B
Front Immunol; 2018; 9():929. PubMed ID: 29755480
[TBL] [Abstract][Full Text] [Related]
4. Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer.
Paul S; Lal G
Int J Cancer; 2016 Sep; 139(5):976-85. PubMed ID: 27012367
[TBL] [Abstract][Full Text] [Related]
5. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
[TBL] [Abstract][Full Text] [Related]
6. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma.
Otto M; Barfield RC; Martin WJ; Iyengar R; Leung W; Leimig T; Chaleff S; Gillies SD; Handgretinger R
Clin Cancer Res; 2005 Dec; 11(23):8486-91. PubMed ID: 16322312
[TBL] [Abstract][Full Text] [Related]
7. Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells.
Rodrigues NV; Correia DV; Mensurado S; Nóbrega-Pereira S; deBarros A; Kyle-Cezar F; Tutt A; Hayday AC; Norell H; Silva-Santos B; Dias S
Cancer Immunol Res; 2018 Apr; 6(4):448-457. PubMed ID: 29358174
[TBL] [Abstract][Full Text] [Related]
8. When less is more: T lymphocyte populations with restricted antigen receptor diversity.
Kronenberg M
J Immunol; 2014 Aug; 193(3):975-6. PubMed ID: 25049427
[No Abstract] [Full Text] [Related]
9. Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation.
Capsomidis A; Benthall G; Van Acker HH; Fisher J; Kramer AM; Abeln Z; Majani Y; Gileadi T; Wallace R; Gustafsson K; Flutter B; Anderson J
Mol Ther; 2018 Feb; 26(2):354-365. PubMed ID: 29310916
[TBL] [Abstract][Full Text] [Related]
10. Neuroblastoma killing properties of Vδ2 and Vδ2-negative γδT cells following expansion by artificial antigen-presenting cells.
Fisher JP; Yan M; Heuijerjans J; Carter L; Abolhassani A; Frosch J; Wallace R; Flutter B; Capsomidis A; Hubank M; Klein N; Callard R; Gustafsson K; Anderson J
Clin Cancer Res; 2014 Nov; 20(22):5720-32. PubMed ID: 24893631
[TBL] [Abstract][Full Text] [Related]
11. Human γδ T cells: From a neglected lymphocyte population to cellular immunotherapy: A personal reflection of 30years of γδ T cell research.
Kabelitz D
Clin Immunol; 2016 Nov; 172():90-97. PubMed ID: 27444042
[No Abstract] [Full Text] [Related]
12. Myeloid-Derived Suppressor Cells Specifically Suppress IFN-γ Production and Antitumor Cytotoxic Activity of Vδ2 T Cells.
Sacchi A; Tumino N; Sabatini A; Cimini E; Casetti R; Bordoni V; Grassi G; Agrati C
Front Immunol; 2018; 9():1271. PubMed ID: 29928279
[TBL] [Abstract][Full Text] [Related]
13. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
Gomes AQ; Martins DS; Silva-Santos B
Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
[TBL] [Abstract][Full Text] [Related]
14. γδ T cells: first line of defense and beyond.
Chien YH; Meyer C; Bonneville M
Annu Rev Immunol; 2014; 32():121-55. PubMed ID: 24387714
[TBL] [Abstract][Full Text] [Related]
15. γδ T cells in cancer immunotherapy.
Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
[TBL] [Abstract][Full Text] [Related]
16. Shared reactivity of V{delta}2(neg) {gamma}{delta} T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells.
Halary F; Pitard V; Dlubek D; Krzysiek R; de la Salle H; Merville P; Dromer C; Emilie D; Moreau JF; Déchanet-Merville J
J Exp Med; 2005 May; 201(10):1567-78. PubMed ID: 15897274
[TBL] [Abstract][Full Text] [Related]
17. Increased frequencies of circulating and tumor-resident Vδ1
Reboursiere E; Gac AC; Garnier A; Salaun V; Reman O; Pham AD; Cabrera Q; Khoy K; Vilque JP; Fruchart C; Chantepie S; Johnson-Ansah H; Macro M; Cheze S; Benabed K; Mear JB; Troussard X; Damaj G; Le Mauff B; Toutirais O
Leuk Lymphoma; 2018 Jan; 59(1):187-195. PubMed ID: 28562153
[TBL] [Abstract][Full Text] [Related]
18. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
19. Tumor-activated TCRγδ⁺ T cells from gastric cancer patients induce the antitumor immune response of TCRαβ⁺ T cells via their antigen-presenting cell-like effects.
Mao C; Mou X; Zhou Y; Yuan G; Xu C; Liu H; Zheng T; Tong J; Wang S; Chen D
J Immunol Res; 2014; 2014():593562. PubMed ID: 24741609
[TBL] [Abstract][Full Text] [Related]
20. Gammadelta T cell receptors without a job.
Kapsenberg ML
Immunity; 2009 Aug; 31(2):181-3. PubMed ID: 19699169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
